Clinical Trial

Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Trial Details
NCT Number NCT07535242
Lead Sponsor Ondokuz Mayıs University
Conditions Multiple Sclerosis
Enrollment 22 participants
Start Date 2026-04-21
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-05-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-17